SIBN - SI-BONE, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.85
-0.91 (-4.61%)
At close: 4:00PM EDT

18.85 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close19.76
Open19.73
Bid15.99 x 900
Ask26.50 x 1300
Day's Range18.45 - 20.03
52 Week Range14.08 - 23.03
Volume109,249
Avg. Volume176,775
Market Cap467.503M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • GuruFocus.com

    Si-bone Inc (SIBN) Chairman, President & CEO Jeffrey W Dunn Sold $785,600 of Shares

    Chairman, President & CEO of Si-bone Inc (30-Year Financial, Insider Trades) Jeffrey W Dunn (insider trades) sold 40,000 shares of SIBN on 08/16/2019 at an average price of $19.64 a share. Continue reading...

  • SI Bone INC (SIBN) Q2 2019 Earnings Call Transcript
    Motley Fool

    SI Bone INC (SIBN) Q2 2019 Earnings Call Transcript

    SIBN earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    SI-BONE, Inc. Reports Second Quarter 2019 Financial Results

    SANTA CLARA, Calif., Aug. 06, 2019 -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.

  • GlobeNewswire

    SI-BONE to Present at the Canaccord Growth Conference on August 8, 2019

    The presentation is set to take place in the Vancouver Room at the InterContinental Boston. The iFuse Implant System is also intended for sacroiliac fusion to augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.

  • GlobeNewswire

    SI-BONE To Report Second Quarter 2019 Financial Results on August 6, 2019

    SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2019 after market close on Tuesday, August 6, 2019. The iFuse Implant System is also intended for sacroiliac fusion to augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.

  • Is SI-BONE, Inc.'s (NASDAQ:SIBN) Balance Sheet A Threat To Its Future?
    Simply Wall St.

    Is SI-BONE, Inc.'s (NASDAQ:SIBN) Balance Sheet A Threat To Its Future?

    SI-BONE, Inc. (NASDAQ:SIBN) is a small-cap stock with a market capitalization of US$493m. While investors primarily...

  • Business Wire

    Survey of 1,000 Women Reveals 8 in 10 are Unaware that Sacroiliac Joint Issues are a Leading Cause of Chronic Lower Back Pain After Pregnancy

    Results of a recent survey of 1,000 women (age 35 to 60) conducted by SI-BONE, Inc. (SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, found that 86% of respondents are unaware that sacroiliac (SI) joint dysfunction is a leading cause of chronic lower back pain for women over 35 who have been pregnant. Studies have shown that the SI joint is the source of pain in 15-30%* of patients with chronic lower back pain and two-thirds† of people impacted by the condition are women. The survey revealed that 65% of respondents experience lower back pain and nearly 30% have been dealing with pain for more than ten years.

  • GlobeNewswire

    SI-BONE’s iFuse Implant System Surpasses 40,000 Procedures

    “It is incredibly gratifying that so many patients who’ve suffered for years with debilitating sacroiliac joint dysfunction are able to regain quality of life following minimally invasive sacroiliac joint fusion with the iFuse Implant System,” said Jeffrey Dunn, President, CEO and Chairman of SI-BONE. Since introducing the iFuse Implant System in 2009, SI-BONE has pioneered a proprietary minimally invasive surgical approach to fuse the sacroiliac joint to treat sacroiliac joint dysfunction.

  • GlobeNewswire

    SI-BONE Announces the Addition of Mark Foley and Heyward Donigan to the Board of Directors

    SI-BONE, Inc., (SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced that Mark J. Foley and Heyward R. Donigan, have joined the company’s Board of Directors. “We are thrilled to welcome both Mark and Heyward to our board of directors,” said Jeff Dunn, President, Chief Executive Officer, and Chairman of SI-BONE. “They both have proven executive experience managing growing businesses, achieving sustainable revenue growth and driving operational improvements which we expect will be invaluable to our organization.

  • GlobeNewswire

    SI-BONE to Present at the 2019 JMP Securities Life Sciences Conference

    SANTA CLARA, Calif., June 05, 2019 -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.

  • SI Bone INC (SIBN) Q1 2019 Earnings Call Transcript
    Motley Fool

    SI Bone INC (SIBN) Q1 2019 Earnings Call Transcript

    SIBN earnings call for the period ending March 31, 2019.

  • Associated Press

    Si-Bone: 1Q Earnings Snapshot

    On a per-share basis, the Santa Clara, California-based company said it had a loss of 38 cents. The medical device maker posted revenue of $15 million in the period. Si-Bone shares have dropped 15% since ...

  • GlobeNewswire

    SI-BONE, Inc. Reports First Quarter 2019 Financial Results

    SANTA CLARA, Calif., May 08, 2019 -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.

  • GlobeNewswire

    SI-BONE to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

    SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management will participate in the upcoming 2019 Bank of America Merrill Lynch Health Care Conference. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.

  • GlobeNewswire

    SI-BONE To Report First Quarter 2019 Financial Results on May 8, 2019

    SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2019 after market close on Wednesday, May 8, 2019. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.

  • Is SI-BONE, Inc. (NASDAQ:SIBN) Worth US$15.13 Based On Its Intrinsic Value?
    Simply Wall St.

    Is SI-BONE, Inc. (NASDAQ:SIBN) Worth US$15.13 Based On Its Intrinsic Value?

    In this article we are going to estimate the intrinsic value of SI-BONE, Inc. (NASDAQ:SIBN) by taking the expected future cash flows and discounting them to today's value. This is done using the Discounted Cash Flow (DCF) mode...

  • GlobeNewswire

    SI-BONE, Inc. Announces FDA Clearance of iFuse Bedrock™ Novel Spinopelvic Fixation Technology

    SI-BONE, Inc. (SIBN), a Silicon Valley based medical device company dedicated to solving musculoskeletal disorders of the spinopelvic anatomy, today announced that it received an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its iFuse Bedrock technology in fusion of the sacroiliac (SI) joint during long construct procedures. With this new broader indication, iFuse Bedrock can now be placed across the SI joint as an adjunct to long fusion procedures with the intent of gaining fusion to augment immobilization and stabilization of the SI joint.

  • GuruFocus.com

    SI-BONE Inc (SIBN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    SI-BONE Inc (NASDAQ:SIBN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • GlobeNewswire

    SI-BONE, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

    SANTA CLARA, Calif., March 07, 2019 -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint.

  • GlobeNewswire

    SI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with  iFuse Implant System® vs Conservative Care

    SANTA CLARA, Calif., March 06, 2019 -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered minimally invasive surgery of the sacroiliac (SI) joint with the.

  • GlobeNewswire

    SI-BONE to Present at the Canaccord Genuity Musculoskeletal Conference

    SI-BONE, Inc., (SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the company will be participating in the upcoming Canaccord Genuity Musculoskeletal Conference in Las Vegas, Nevada. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.

  • GlobeNewswire

    SI-BONE To Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

    SI-BONE, Inc. (SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced it will report financial results for the fourth quarter and full year 2018 financial results after market close on Thursday, March 7, 2019.

  • PrinterPrezz to Work With SI-BONE to Speed Innovation in Metal 3D Printed Orthopedic Medical Devices
    Business Wire

    PrinterPrezz to Work With SI-BONE to Speed Innovation in Metal 3D Printed Orthopedic Medical Devices

    PrinterPrezz, Inc., a trailblazer in combining metal 3D printing, nanotechnologies and surgical expertise to design and manufacture next generation medical devices, today announced that it has signed a customer agreement with SI-BONE, Inc. (SIBN), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®. As part of the agreement, PrinterPrezz will provide SI-BONE with development and build services for potential future 3D-printed advanced medical devices and implants.

  • GlobeNewswire

    Shockwave Appoints Laura Francis to Board of Directors

    SANTA CLARA, Calif., Feb. 07, 2019 -- Shockwave Medical, a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified.

  • GlobeNewswire

    SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuse

    SANTA CLARA, Calif., Feb. 04, 2019 -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered minimally invasive surgery of the sacroiliac (SI) joint with the.